Invesaro

Stocks Comparison

AbbVie vs Johnson & Johnson: revenue, profit, margins and growth compared

AbbVie brought in $61.2B of revenue in fiscal 2025, Johnson & Johnson $94.2B in fiscal 2025. Revenue changed by +8.6% at AbbVie and +6.0% at Johnson & Johnson on the year before, so AbbVie grew faster. AbbVie kept 6.9% of its revenue as net profit, Johnson & Johnson 28.5%. Free cash flow was $17.8B at AbbVie and $19.7B at Johnson & Johnson.

Side by side, latest fiscal year

ABBVJNJ
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 28, 2025)
Revenue$61.2B$94.2B
Revenue growth+8.6%+6.0%
Net income$4.2B$26.8B
Net margin6.9%28.5%
Free cash flow$17.8B$19.7B
Free cash flow margin29.1%20.9%
Earnings per share (diluted)$2.36$11.03
Cash$5.2B$19.7B
Debt$64.5B$41.4B
Price to earnings112.024.6
Market value$467.1B$653.6B
Dividend yield2.52%1.90%
Rank by revenue in sector#14 of 523 · Health care#9 of 523 · Health care

Over the years

Revenue
ABBV FY2018: $32.8BABBV FY2019: $33.3BABBV FY2020: $45.8BABBV FY2021: $56.2BABBV FY2022: $58.1BABBV FY2023: $54.3BABBV FY2024: $56.3BABBV FY2025: $61.2BJNJ FY2018: $81.6BJNJ FY2019: $82.1BJNJ FY2020: $82.6BJNJ FY2021: $78.7BJNJ FY2022: $80BJNJ FY2023: $85.2BJNJ FY2024: $88.8BJNJ FY2025: $94.2BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $61.2BJNJ $94.2B
Net income
ABBV FY2018: $5.7BABBV FY2019: $7.9BABBV FY2020: $4.6BABBV FY2021: $11.5BABBV FY2022: $11.8BABBV FY2023: $4.9BABBV FY2024: $4.3BABBV FY2025: $4.2BJNJ FY2018: $15.3BJNJ FY2019: $15.1BJNJ FY2020: $14.7BJNJ FY2021: $20.9BJNJ FY2022: $17.9BJNJ FY2023: $35.2BJNJ FY2024: $14.1BJNJ FY2025: $26.8BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $4.2BJNJ $26.8B
Net margin
ABBV FY2018: 17.4%ABBV FY2019: 23.7%ABBV FY2020: 10.1%ABBV FY2021: 20.5%ABBV FY2022: 20.4%ABBV FY2023: 9.0%ABBV FY2024: 7.6%ABBV FY2025: 6.9%JNJ FY2018: 18.8%JNJ FY2019: 18.4%JNJ FY2020: 17.8%JNJ FY2021: 26.5%JNJ FY2022: 22.4%JNJ FY2023: 41.3%JNJ FY2024: 15.8%JNJ FY2025: 28.5%FY18FY19FY20FY21FY22FY23FY24FY25
ABBV 6.9%JNJ 28.5%
Revenue growth
ABBV FY2019: +1.6%ABBV FY2020: +37.7%ABBV FY2021: +22.7%ABBV FY2022: +3.3%ABBV FY2023: -6.4%ABBV FY2024: +3.7%ABBV FY2025: +8.6%JNJ FY2019: +0.6%JNJ FY2020: +0.6%JNJ FY2021: -4.7%JNJ FY2022: +1.6%JNJ FY2023: +6.5%JNJ FY2024: +4.3%JNJ FY2025: +6.0%FY19FY20FY21FY22FY23FY24FY25
ABBV +8.6%JNJ +6.0%
Free cash flow
ABBV FY2018: $12.8BABBV FY2019: $12.8BABBV FY2020: $16.8BABBV FY2021: $22BABBV FY2022: $24.2BABBV FY2023: $22.1BABBV FY2024: $17.8BABBV FY2025: $17.8BJNJ FY2018: $18.5BJNJ FY2019: $19.9BJNJ FY2020: $20.2BJNJ FY2021: $19.8BJNJ FY2022: $17.2BJNJ FY2023: $18.2BJNJ FY2024: $19.8BJNJ FY2025: $19.7BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $17.8BJNJ $19.7B

Fiscal years as each company reports them; the two may end in different months.

Questions about AbbVie and Johnson & Johnson

Which is bigger by revenue, AbbVie or Johnson & Johnson?

Johnson & Johnson is bigger by revenue: $94.2B in fiscal 2025, against $61.2B for AbbVie in fiscal 2025.

Which keeps more of its revenue as profit, AbbVie or Johnson & Johnson?

AbbVie had a net margin of 6.9% in fiscal 2025; Johnson & Johnson had 28.5% in fiscal 2025.

Which grew revenue faster, AbbVie or Johnson & Johnson?

In their latest fiscal years revenue changed by +8.6% at AbbVie and +6.0% at Johnson & Johnson.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies